Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
Workers' Comp
White Paper
Substance Misuse Recovery Network
Specialty Networks Play a Key Role in Fighting Opioid Misuse For all the progress our nation has made in reducing opioid prescriptions, m
Mitchell
News Release
In a Hazy Election, Marijuana Is a Clear Winner
As ballots continue to be counted around the country, with some races still too close to call, voters were much more certain on their support for m
Mitchell
News Release
Evzio Naloxone Auto-Injectors Discontinued
Kaleo, the makers of Evzio, have recently discontinued the prod
Workers' Comp
News Release
Business Insurance: Lack of guidelines complicates COVID-19 care
Evidence-based medicine is a mainstay in the workers compensation industry, and those aiming to treat workers with COVID-19 are relying on an
Workers' Comp
Blog
Look for a Broken Spirit, Not Just a Broken Bone
As featured on the workcompwire.com blog, this piece was contributed by Tammy Bradly, Vice President, Clinical Product Develo
Mitchell
News Release
FDA Approves Veklury (Remdesivir) for Treatment of Hospitalized COVID-19 Patients
On October 22, 2020, the Food and Drug Administration (FDA)